Lv5
1310 积分 2024-03-29 加入
When Patients Refuse Radical Cystectomy: Integrating Trimodality Therapy in the Perioperative ICI/ADC Era
2天前
求助中
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
12天前
已完结
Pragmatic Clinical End points for High-risk NMIBC: A Path to Accelerated Market Access in Europe
12天前
已完结
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study
1个月前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
2个月前
已完结
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer
3个月前
已完结
HER2 and urothelial carcinoma: current understanding and future directions
8个月前
已完结
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer
9个月前
已完结
Muscle-Invasive Bladder Cancer: A Watershed Moment
9个月前
已完结
A single-arm, multicenter, phase 2 clinical study of recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate (MRG002) in HER2-positive unresectable locally advanced or metastatic urothelial carcinoma
9个月前
已完结
皖公网安备34019202002308
